Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CanAm Bioresearch and EpiTherapeutics, a developer of novel cancer drugs, have entered into a medicinal chemistry research services pact to develop new anti-cancer drugs.
Subscribe to our email newsletter
CanAm Bioresearch is a contract research organization (CRO) engaged in pre-clinical discovery and development, particularly focused on medicinal chemistry.
EpiTherapeutics R&D EVP Lars-Ole Gerlach said they are very pleased to enter into a formalized drug discovery collaboration with CanAm, after working with their team for the past several months.
"We look forward to a fruitful collaboration with the aim of developing novel anti-cancer drugs within the promising new area of epigenetics," Gerlach said.